News: CSL Csl Behring Receives FDA Approval For Hizentra® (Immune Globulin Subcutaneous <Origin..., page-4

  1. 675 Posts.
    lightbulb Created with Sketch. 133
    Hard to say whether this will have a material change to revenues. Per the 2022 annual report, Hizentra sales were up 20% during 2022 and is the market leading product for subcutaneous immunoglobulin products.

    Page 15 of the annual report shows that patients have a preference for Hizentra for at home dosing, so the pre-filled syringe is an obvious move to make.

    Appears to not be all upside as this has lead to a decline in Privigen sales.

    DYOR, IMO, blah blah
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$262.05
Change
6.740(2.64%)
Mkt cap ! $127.0B
Open High Low Value Volume
$258.12 $263.22 $257.91 $78.14M 298.9K

Buyers (Bids)

No. Vol. Price($)
5 52 $262.05
 

Sellers (Offers)

Price($) Vol. No.
$262.07 56 6
View Market Depth
Last trade - 11.18am 22/07/2025 (20 minute delay) ?
CSL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.